Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Department of Surgery and Cancer, Imperial College London, Du Cane Road, W12 0HS, London, UK.
Trends Cancer. 2024 Jun;10(6):475-477. doi: 10.1016/j.trecan.2024.04.003. Epub 2024 May 9.
The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.
美国食品和药物管理局 (FDA) 批准 lifileucel 用于晚期黑色素瘤,这是首个用于实体瘤的细胞疗法进入临床应用。在此,我们总结了这一具有里程碑意义的批准,探讨了相关的监管途径,并评估了为确保这种先进的“活”疗法有效实施而仍然存在的挑战。